Skip to main content
. 2015 Sep 1;192(5):551–558. doi: 10.1164/rccm.201503-0426OC

Table 6.

Treatment Failure Odds by Specific Therapy

Therapy Age ≥30
Age <30
Age ≥ 30 vs. Age < 30
Failures/Total Failure (%) Failures/Total Failure (%) OR (95% CI) P Value
All treatments 100/579 17.3 64/621 10.3 1.82 (1.30–2.54) <0.001*
All LABA 69/203 34.0 35/145 24.1 1.62 (1.0–2.61) 0.049*
 LABA + ICS 22/109 20.2 7/75 9.3 2.46 (0.99–6.09) 0.052
 LABA + leukotriene 28/58 48.3 10/33 30.3 2.15 (0.87–5.30) 0.098
 LABA only 19/36 52.8 18/37 48.7 1.18 (0.47–2.96) 0.724
No LABA 31/376 8.2 29/476 6.1 1.39 (0.82–2.34) 0.224
All vs. no LABA Comparison of ORs
0.668
All ICS 31/243 12.8 12/241 5.0 2.79 (1.40–5.57) 0.004*
 LABA + ICS LABA section
 ICS only 9/134 6.7 5/166 3.0 2.32 (0.76–7.09) 0.140
No ICS 69/336 20.5 52/380 13.7 1.63 (1.10–2.42) 0.015*
All vs. no ICS Comparison of ORs
0.186
All leukotriene 29/99 29.3 11/75 14.7 2.41 (1.11–5.22) 0.026*
LABA + leukotriene LABA section
Leukotriene only 1/41 2.4 1/42 2.4 1.02 (0.06–16.95) 0.986
No leukotriene 71/480 14.8 53/546 9.7 1.61 (1.11–2.36) 0.013*
All vs. no leukotriene Comparison of ORs
0.361
All short-acting β-agonist (only) 3/63 4.8 4/86 4.7 1.02 (0.22–4.75) 0.975
No short-acting β-agonist 97/516 18.8 60/535 11.2 1.83 (1.29–2.59) <0.001*
All vs. no short-acting β-agonist Comparison of ORs
0.469
All placebo (only) 18/138 13.0 19/182 10.4 1.29 (0.65–2.56) 0.471
No placebo 82/441 18.6 45/439 10.3 2.0 (1.35–2.96) <0.001*
All vs. no placebo Comparison of ORs 0.274

Definition of abbreviations: CI = confidence interval; ICS = inhaled corticosteroid; LABA = long-acting β-agonist; OR = odds ratio.

Significant exacerbations for DICE, IMPACT, SMOG, and PRICE (which had no treatment failures) were counted as treatment failures.

*

P < 0.05, all P values and ORs from logistic regression.

Tests the significance of the difference in ORs in the age group between the therapy groups.